Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Umoja Biopharma Announces $100 Million Series C Financing Co-Led by Double Point Ventures and DCVC Bio

Jan 14, 2025•over 1 year ago

Contract Type

partnership

SeattleBiotechnologyTherapeutics

Description

Umoja Biopharma, Inc. announced the closing of a $100 million Series C financing, co-led by Double Point Ventures and DCVC Bio, to support the clinical development of VivoVec™ derived in vivo CAR T cells.

Company Information

Company

Umoja Biopharma

Location

1150 Eastlake Ave E, Suite 400

Seattle, Washington, United States

About

Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Umoja Biopharma's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months